secwatch.observer — SEC 8-K summary
======================================

Issuer:     MEDIFAST INC (MED)
CIK:        0000910329
Form:       8-K
Filed at:   2026-05-26T20:26:14+00:00
Accession:  0001628280-26-038109
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 5.07, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Medifast appoints Nicholas Johnson as CEO; Dan Chard becomes non-executive Chairman
--------------------------------------------------------------------------------

- Nicholas Johnson, 46, becomes CEO effective June 1, 2026; Dan Chard transitions to non-executive Chairman.
- Johnson's compensation: $600K base salary, target bonus 100% of base, LTI target 250% of base (69% increase vs. prior role).
- Stockholders approved Amended 2012 Share Incentive Plan, increasing authorized shares by 250,000.
- All seven director nominees elected; say-on-pay and auditor ratification passed.
- Johnson joined Medifast in 2018, most recently as President; prior senior roles at Nu Skin Enterprises.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/910329/000162828026038109/0001628280-26-038109-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/910329/000162828026038109/med-20260519.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-038109

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer